In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Making The Most Of A Renaissance Moment In Health Care

The Many Good Things To Emerge From The Havoc Wrought By COVID Must Not Be Squandered

Executive Summary

The rise of digital alongside long-established physical methods of care delivery should not give rise to notions of an "either/or" choice, but should rather be seen as an “and,” said Accenture’s Andrew Meade in conversation with In Vivo.

You may also be interested in...



How COVID Boosted Medtech In The Eyes Of The World

Reaching deep and being resourceful were the in-demand attributes that medtech industry leaders brought to bear when the COVID-19 pandemic stretched health care providers almost to breaking point.

AI Medical Imaging And Radiotherapy First For UK’s NICE

Inaugural artificial intelligence recommendations from NICE on radiotherapy contouring should allow clinicians to spend more time with patients and on complex cases where AI is not an option. But large language models are not appropriate in all cases, cautions Adrian Sutherland, principal healthcare architect at Endava consultancy.

AI Medical Imaging And Radiotherapy First For UK’s NICE

Inaugural artificial intelligence recommendations from NICE on radiotherapy contouring should allow clinicians to spend more time with patients and on complex cases where AI is not an option. But large language models are not appropriate in all cases, cautions Adrian Sutherland, principal healthcare architect at Endava consultancy.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV124820

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel